ABBV vs ADM Stock Comparison

Scores Breakdown

Metric	ABBV	ADM
📈 Growth	26/30	26/30
💰 Profitability	18/20	16/20
🏦 Financial Health	6/20	18/20
💵 Valuation	12/20	14/20
⚠️ Risk (lower is better)	8/10	7/10
Overall Score	64/100	77/100

Side-by-Side Summaries

ABBV Analysis	ADM Analysis
📈 Growth & Financial Trajectory Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2). 💰 Margins & Cash Flow Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters. 🛡️ Balance Sheet & Liquidity Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations. ⚠️ Key Drivers & Risks Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power. Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.	📈 Growth & Financial Trajectory Over the 8 quarters, Revenues progressed from about $21.50B (2024 Q4) to $22.68B (2026 Q2), with a mid-period trough in 2025 Q4 near $18.56B. Net income rose from about $0.42B to roughly $0.91B by 2026 Q2, though 2025 saw a dip before the rebound. The 8-quarter trend shows growth, albeit choppy, culminating in a clear earnings acceleration on a year-over-year basis. 💰 Margins & Cash Flow Gross margin expanded from the mid single digits (roughly 6.4%–7%) to around 9% in 2026 Q1 and roughly 8.5% in 2026 Q2, signaling better product mix and leverage. Operating margin ran in the low-to-mid single digits, reflecting ongoing efficiency gains amid revenue volatility. Operating cash flow remained positive for most quarters; 2026 Q1 shows strong cash from operations, while 2026 Q2 recorded a net cash outflow driven by investing/financing activities. Investing cash flow remained negative as capex/activity persisted. 🛡️ Balance Sheet & Liquidity Assets of about $52–53B supported by equity around $22–23B and liabilities of roughly $29–30B, yielding solid leverage metrics. Current assets > current liabilities in most periods, with a healthy liquidity cushion and modest long-term debt (~$7.6B). ⚠️ Key Drivers & Risks Drivers: Demand in food/agri value chain; favorable margin trajectory from mix improvement and cost discipline. Risks: Commodity/price cycles and cyclicality; potential valuation sensitivity to commodity and macro shifts.

ABBV Analysis

ADM Analysis

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2).

💰 Margins & Cash Flow

Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations.

⚠️ Key Drivers & Risks

Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power.
Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.

📈 Growth & Financial Trajectory

Over the 8 quarters, Revenues progressed from about $21.50B (2024 Q4) to $22.68B (2026 Q2), with a mid-period trough in 2025 Q4 near $18.56B. Net income rose from about $0.42B to roughly $0.91B by 2026 Q2, though 2025 saw a dip before the rebound. The 8-quarter trend shows growth, albeit choppy, culminating in a clear earnings acceleration on a year-over-year basis.

💰 Margins & Cash Flow

Gross margin expanded from the mid single digits (roughly 6.4%–7%) to around 9% in 2026 Q1 and roughly 8.5% in 2026 Q2, signaling better product mix and leverage.
Operating margin ran in the low-to-mid single digits, reflecting ongoing efficiency gains amid revenue volatility.
Operating cash flow remained positive for most quarters; 2026 Q1 shows strong cash from operations, while 2026 Q2 recorded a net cash outflow driven by investing/financing activities. Investing cash flow remained negative as capex/activity persisted.

🛡️ Balance Sheet & Liquidity

Assets of about $52–53B supported by equity around $22–23B and liabilities of roughly $29–30B, yielding solid leverage metrics. Current assets > current liabilities in most periods, with a healthy liquidity cushion and modest long-term debt (~$7.6B).

⚠️ Key Drivers & Risks

Drivers: Demand in food/agri value chain; favorable margin trajectory from mix improvement and cost discipline.
Risks: Commodity/price cycles and cyclicality; potential valuation sensitivity to commodity and macro shifts.

Similar Companies

ABT Score: 71 AMGN Score: 67 BMY Score: 72 GILD Score: 46 JNJ Score: 86 LLY Score: 82 MRK Score: 58 MRNA Score: 38 PFE Score: 55

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"